Lung Cancer Research Highlights Need for Improved Patient Selection

Researchers have emphasized the importance of developing prognostic and predictive biomarkers to improve patient selection in lung cancer treatment. This research, conducted at Maastricht University Medical Center, highlights the need for more effective strategies in managing the disease.

Key Takeaways:

• Lung cancer is the leading cause of cancer-related death worldwide, with a poor overall prognosis despite advancements in immunotherapy and targeted agents.
• Liquid biopsies are being explored as a feasible alternative to serial lung tumor tissue biopsies for prognostic and predictive biomarker analysis.
• Radiotherapy, commonly used alongside systemic treatments, can induce the release of immuno-stimulatory and immuno-suppressive molecules, triggering immune- and inflammatory responses.
• The research identified certain immune-related molecules, including cytokines and chemokines, damage-associated molecular patterns, soluble receptors and ligands, and proteins expressed on the immune cell surface of circulating immune cells, which have potential prognostic and/or predictive value in patients with lung cancer treated with radiotherapy.
• Classical cytokines IL-6, IL-8, and TGF-b1 were the most studied molecules in patients with lung cancer treated with radiotherapy and were associated with poor survival and increased risk of radiation-induced toxicity.
• Despite promising findings, there are still barriers to implementing these results in regular clinical practice, and practical points to achieve this goal are addressed in the review.
• The study suggests the potential of immunotherapy and targeted agents in improving patient outcomes, but emphasizes the need for more effective patient selection and treatment strategies.

Statistics:

• According to the research, lung cancer is the leading cause of cancer-related death worldwide.
• The overall prognosis for patients with advanced stage lung cancer remains poor despite advancements in immunotherapy and targeted agents.
• 15% of lung cancer patients experience radiation-induced toxicity.
• IL-6, IL-8, and TGF-b1 are the most studied cytokines associated with poor survival in patients with lung cancer treated with radiotherapy.

Sources:

• Research Reports from Maastricht University Medical Center Provide New Insights into Lung Cancer (The prognostic and predictive value of peripheral immune-related proteins in patients with lung cancer treated with radiotherapy). Immunotherapy Weekly. August 6, 2025; p 3907.
• The prognostic and predictive value of peripheral immune-related proteins in patients with lung cancer treated with radiotherapy. Frontiers in Oncology, 2025,15.